Terrie Curran
Terrie Curran's purchase track record
Terrie Curran has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/6/2023 | PHAT | $101K | +79.1% | +36.4% | +3.7% |
| 5/13/2022 | PHAT | $152K | +33.2% | +32.5% | -0.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
PHAT launches Phase 3 study for VOQUEZNA in GERD. Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.
Transaction History
| ARQT | ▲ Buy | Option Exercise | 11,148 | $84K | 8/27/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 11,148 | $279K | 8/27/2026 | View on chart |
| ARQT | ▲ Buy | Option Exercise | 27,052 | $233K | 8/27/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 27,052 | $677K | 8/27/2026 | View on chart |
| ARQT | ▲ Buy | Option Exercise | 1,072 | $8K | 8/20/2026 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,072 | $28K | 8/20/2026 | View on chart |
| ARQT | ▲ Buy | Grant | 5,778 | $0 | 6/5/2026 | View on chart |
| ARQT | ▲ Buy | Grant | 7,609 | $0 | 6/12/2025 | View on chart |
| PHAT | ▼ Sell | Open Market | 19,109 | $126K | 1/21/2025 | View on chart |
| ARQT | ▼ Sell | Open Market | 8,687 | $94K | 11/11/2024 | View on chart |
| PHAT | ▼ Sell | Open Market | 33,848 | $397K | 7/15/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 10,139 | $0 | 6/14/2024 | View on chart |
| PHAT | ▼ Sell | Open Market | 16,851 | $154K | 3/22/2024 | View on chart |
| PHAT | ▲ Buy | Grant | 37,500 | $0 | 11/1/2023 | View on chart |
| PHAT | ▲ Buy | Grant | 200,000 | — | 7/14/2023 | View on chart |
| ARQT | ▲ Buy | Grant | 4,375 | $0 | 5/31/2023 | View on chart |
| PHAT | ▲ Buy | Open Market | 12,919 | $101K | 4/6/2023 | View on chart |
| PHAT | ▼ Sell | Open Market | 1,436 | $12K | 3/1/2023 | View on chart |
| PHAT | ▼ Sell | Open Market | 5,821 | $48K | 1/20/2023 | View on chart |
| PHAT | ▲ Buy | Grant | 97,500 | $0 | 1/19/2023 | View on chart |
| PHAT | ▼ Sell | Open Market | 1,526 | $15K | 11/21/2022 | View on chart |
| PHAT | ▲ Buy | Grant | 7,500 | $0 | 9/1/2022 | View on chart |
| ARQT | ▲ Buy | Grant | 4,312 | $0 | 6/1/2022 | View on chart |
| PHAT | ▲ Buy | Grant | 12,000 | $0 | 5/19/2022 | View on chart |
| PHAT | ▲ Buy | Open Market | 20,500 | $152K | 5/13/2022 | View on chart |
| PHAT | ▲ Buy | Grant | 41,250 | $0 | 1/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade
Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade. Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.